Max Healthcare Institute balance sheet

As of Sep 2026

Total assets: ₹18,722cr+15.0% on Sep 2025
Shareholders' equity: ₹11,533cr+14.7% on Sep 2025
Total debt: ₹3,795cr+15.9% on Sep 2025
Cash and investments: ₹557cr+16.5% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	7,764	6,980	5,462	3,246	2,019
	805	592	900	445	207
	4.7	4.7	4.7	63.0	0.0
	3,689	3,488	3,480	2,952	2,455
	2,499	2,518	2,555	2,522	2,565
	9.5	0.8	0.3	108	45.9
	5.5	5.5	2.9	2.1	0.5
	840	746	383	138	138
	73.5	79.2	88.8	96.6	103
	233	204	204	230	206
	1,152	1,035	679	467	448
	32.0	46.5	28.0	0.0	0.0
	671	621	512	490	420
	16,626	15,286	13,622	10,294	8,159
	132	114	106	79.8	76.2
	1,243	970	687	463	336
	557	666	662	980	42.8
	14.3	34.8	20.3	119	1,425
	9.9	0.0	10.4	0.0	0.0
	69.9	70.6	58.1	41.3	30.5
	1,894	1,741	1,438	1,603	1,835
	65.9	54.8	48.7	19.1	16.3
	2,096	1,945	1,593	1,706	1,943
	18,722	17,231	15,214	12,000	10,102
Equity
	973	973	972	972	971
	10,359	9,774	8,409	7,436	6,439
	11,332	10,747	9,381	8,408	7,410
	201	0.0	0.0	0.0	0.0
	11,533	10,747	9,381	8,408	7,410
Liabilities
	3,171	2,978	2,768	1,188	604
	323	269	272	340	320
	3,494	3,247	3,040	1,529	924
	139	128	98.1	75.5	60.5
	826	688	648	515	437
	237	235	234	224	225
	4,696	4,297	4,020	2,343	1,647
	624	500	243	110	84.5
	997	859	808	677	543
	575	573	522	282	285
	2,196	1,932	1,572	1,070	913
	118	81.4	78.8	61.2	48.4
	178	174	163	118	84.7
	2,493	2,187	1,814	1,249	1,046
	7,189	6,484	5,834	3,592	2,692
	18,722	17,231	15,214	12,000	10,102
Assets — additional as-filed lines
	4.5	34.8	138	3.9	15.8
Trade payables — MSME split
	13.0	12.6	8.3	5.5	3.9
	984	846	800	627	540

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MAXHEALTH₹815.00

Max Healthcare Institute Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP FORTIS MEDANTA DRREDDY CIPLA SUNPHARMA DIVISLAB TORNTPHARMMcap ₹79,310 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	2,019.1	3,245.8	5,461.9	6,980.0	7,763.8
+ Capital Work-in-Progress	206.6	445.3	900.5	592.2	804.5
+ Investment Property	0.0	63.0	4.7	4.7	4.7
+ Goodwill	2,454.7	2,952.5	3,480.3	3,488.2	3,689.2
+ Other Intangibles	2,565.0	2,522.4	2,554.7	2,518.2	2,499.3
+ Intangibles under Development	45.9	107.8	0.3	0.8	9.5
+ Non-current Investments	0.5	2.1	2.9	5.5	5.5
+ Long-term Loans	138.5	138.5	383.5	746.5	840.0
+ Trade Receivables — Non-current	102.8	96.6	88.8	79.2	73.5
+ Other Non-current Financial Assets	206.0	230.1	204.0	203.9	233.2
Non-current Financial Assets	447.8	467.3	679.1	1,035.0	1,152.1
+ Deferred Tax Assets	0.0	0.0	28.0	46.5	32.0
+ Other Non-current Assets	419.8	489.8	512.4	620.6	671.0
Total Non-current Assets	8,158.8	10,293.8	13,621.9	15,286.2	16,625.9
Current Assets
+ Inventories	76.2	79.8	106.2	114.3	131.8
+ Trade Receivables	336.1	462.7	687.3	969.8	1,243.4
+ Cash & Cash Equivalents	42.8	979.8	661.6	665.8	556.7
+ Other Bank Balances	1,425.3	119.4	20.3	34.8	14.3
+ Short-term Loans	0.0	0.0	10.4	0.0	9.9
+ Other Current Financial Assets	30.5	41.3	58.1	70.6	69.9
Current Financial Assets	1,834.7	1,603.3	1,437.7	1,740.9	1,894.1
+ Other Current Assets	16.3	19.1	48.7	54.8	65.9
Total Current Assets	1,943.1	1,706.2	1,592.6	1,944.8	2,096.3
Total Assets	10,101.9	11,999.9	15,214.5	17,230.9	18,722.1
Equity
+ Equity Share Capital	970.9	971.9	972.1	973.1	973.3
+ Other Equity / Reserves	6,438.7	7,436.2	8,408.7	9,773.5	10,358.7
Equity — Owners of Parent	7,409.6	8,408.1	9,380.9	10,746.6	11,332.0
+ Minority Interest	0.0	0.0	0.0	0.0	201.1
Total Equity	7,409.6	8,408.1	9,380.9	10,746.6	11,533.1
Liabilities
+ Borrowings — Non-current	604.5	1,188.5	2,767.6	2,978.0	3,171.0
+ Other Non-current Financial Liab	319.6	340.1	272.4	268.6	322.8
Non-current Financial Liabilities	924.0	1,528.5	3,040.0	3,246.6	3,493.7
+ Provisions — Non-current	60.5	75.5	98.1	127.8	139.2
+ Deferred Tax Liabilities	437.1	514.9	648.2	687.5	825.9
+ Other Non-current Liabilities	225.1	224.3	233.6	235.5	237.5
Non-current Liabilities	1,646.7	2,343.1	4,019.8	4,297.4	4,696.2
+ Borrowings — Current	84.5	110.5	242.7	500.4	624.1
+ Trade Payables	543.5	677.5	807.9	859.0	997.1
+ Other Current Financial Liab	284.6	281.6	521.8	572.5	575.3
Current Financial Liabilities	912.5	1,069.6	1,572.4	1,932.0	2,196.5
+ Provisions — Current	48.4	61.2	78.8	81.4	118.1
+ Other Current Liabilities	84.7	118.0	162.5	173.6	178.2
Current Liabilities	1,045.6	1,248.7	1,813.8	2,186.9	2,492.8
Total Liabilities	2,692.3	3,591.8	5,833.6	6,484.3	7,189.0
Total Equity & Liabilities	10,101.9	11,999.9	15,214.5	17,230.9	18,722.1
Assets — additional as-filed lines
+ Current Tax Assets	15.8	3.9	138.3	34.8	4.5
Trade Payables — MSME split
+ Dues to Micro & Small — Current	3.9	5.5	8.3	12.6	13.0
+ Dues to Other Creditors — Current	539.6	627.5	799.7	846.4	984.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.